Real-world effectiveness and safety of xanomeline and trospium for treatment-resistant schizophrenia in a state hospital system
Bibliographic Data
| ID | 15526850 |
|---|---|
| Authors | Nina Vadiei (0000-0003-3984-0317, Austin College, corresponding author), M Lynn Crismon (Austin College) |
| Year | 2026 |
| Volume | 16 |
| Pages | 1736922-1736922 |
| Publication date | 2026-01-30 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2025.1736922 |
| PMID | 41694131 |
| OpenAlex | W7126176007 |
| Language | EN |
| Citations received | 1 |
| References cited | 23 |
In inpatients with TRS taking adjunct DRBAs (including anticholinergic DRBAs) XT use was commonly discontinued due to intolerability/ineffectiveness. Larger controlled trials are needed to further investigate XT's effectiveness for treating TRS and determine how adjunct anticholinergic use impacts its safety/efficacy
Adjunct · Anticholinergic · Anticholinergic agents · Augment · Clinical trial · Psychosis · Schizophrenia (object-oriented programming · Bipolar Disorder and Treatment · Schizophrenia research and treatment · Sleep and related disorders
| Citations per year | 1 |
|---|---|
| Citation span | 2026 - 2026 (1) |
| Highly cited | No |